Helix | Life Sciences

Unlock the world's most dynamic precision medicine network

Clinico-genomics for Autoimmune drug discovery and development

Accelerate research across a range of inflammation and immunology conditions with the largest continously growing clinico-genomic registry with full patient consent for use and recontact.

Comprehensive Whole Exome Sequencing Platform

The first and only FDA de novo class II authorized exome platform (Exome+®) optimized to be the most comprehensive and technically sensitive WES offering available.

Longitudinal Clinical Insights

De-identified, OMOP-standardized EHR integrations, including full clinical data & lab results, across North America. Regular data refreshes enable life sciences to follow the patient journey beyond an initial encounter.

Diverse Claims Data

Insights into medication usage, treatment adherence and cost of care through access to medical, pharmacy and mortality data from a partnership with Komodo Health.

Proprietary Clinico-Genomic Registry & Support

- Exome+® sequencing data linked with rich longitudinal clinical data from health system partners across NA
- Multi-site network protocol aggregating cohorts for a range of therapeutic areas
- Geographically and genetically diverse population consented for Life Sciences recontact
- World class analytical capabilities and a dedicated in-house Translational Research team

Let the power of Exome+® drive your drug discovery and preclinical research

Target Identification and Validation | **New Biomarker Discovery** | **Evidence and Outcomes Research**

For more information, visit or email us.
helix.com/life-sciences | Lifesciences@helix.com

Helix | Life Sciences

Linked clinico-genomic cohort of autoimmune conditions

15.6 years
on average of longitudinal patient history

~29K
clinico-genomic records of autoimmune patients

15
conditions with at least 100 diagnosed patients

% of Patients by Age Range



% of patients with X number of measurements



Major conditions analyzed include:
Lupus, Psoriasis, Rheumatoid Arthritis, Multiple Sclerosis, Crohn's Disease, Ulcerative Colitis, Hashimoto's and many more!

TL1A (TNFSF15) **genotype affects the long-term therapeutic outcomes of anti-TNFa-antibodies for Crohn's disease patients**
2020 study by Endo K. et. al

1. Investigated naïve CD patients treated with antibody therapy and anti-TNFa between *TLA1* and control groups
2. Results indicated that design of customized therapy with anti-TNF antibodies using *TL1A* genomic information could be effective in the future.

Helix's linked clinico-genomic data enable life sciences to expand similar studies and drive therapeutic development by:

- Building clinico-genomic cohort and gather prescription data and PRS deployment
- Test rare-variant gene burden in all patients and those with high PRS but no disease
- Analyze Impact of *TL1A* on outcomes after anti-TNFa antibodies and other treatments

For more information, visit or email us.
helix.com/life-sciences | Lifesciences@helix.com